Endovascular

View the latest content related to this topic

News • Interventional

Abre Venous Stent Meets 30-Day, 1-Year Targets in Pivotal IDE Trial

If approved by the FDA, this device will join two others designed specifically for use in the veins.

Caitlin E. Cox

June 18, 2020

Slides

See all

Presentation

ACC 2020

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

Presenter: William Hiatt

March 29, 2020

Presentation

TAVI: Cerebral Protection for Everyone

Presenter: Susheel Kodali

December 10, 2019

Long-term Safety and Efficacy in Continued Access Left Atrial Appendage Closure Registries

December 02, 2019

Presentation

CACI 2019

¿Qué papel juegan actualmente los nuevos anticoagulantes en la prevención del stroke?

Presenter: Nicolás Gonzalez

November 29, 2019

Presentation

CACI 2019

ACV en Argentina Datos poblacionales

Presenter: Sebastián F. Ameriso

November 29, 2019

News

See all

Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2020

By Shelley Wood

July 02, 2020

News • Interventional

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

By L.A. McKeown

July 02, 2020

News

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

By L.A. McKeown

June 29, 2020

News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

By Caitlin E. Cox

June 25, 2020

News • Interventional

Abre Venous Stent Meets 30-Day, 1-Year Targets in Pivotal IDE Trial

By Caitlin E. Cox

June 18, 2020

TCT 2020

October 14

October 18, 2020

TCT 2020 Call For Science

October 14

October 18, 2020

ISC 2020

February 19

February 21, 2020

Controversies & Advances 2019

November 14

November 15, 2019

Videos on This Topic

See all

REGISTER for free or LOG IN to view this content

June 14, 2019

Advertisement

Endovascular

Abre Venous Stent Meets 30-Day, 1-Year Targets in Pivotal IDE Trial

Slides

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

TAVI: Cerebral Protection for Everyone

Long-term Safety and Efficacy in Continued Access Left Atrial Appendage Closure Registries

¿Qué papel juegan actualmente los nuevos anticoagulantes en la prevención del stroke?

ACV en Argentina Datos poblacionales

News

TCTMD’s Top 10 Most Popular Stories for June 2020

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

Abre Venous Stent Meets 30-Day, 1-Year Targets in Pivotal IDE Trial

More on This Topic

Upcoming Conferences

TCT 2020

TCT 2020 Call For Science

Conference Coverage

ISC 2020

Controversies & Advances 2019

Videos on This Topic

REGISTER for free or LOG IN to view this content

Advertisement

Advertisement

Endovascular

Slides

News

More on This Topic

Upcoming Conferences

Conference Coverage

Videos on This Topic

REGISTER for free or LOG IN to view this content

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content